Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma

Cancer Gene Therapy

Volumn 7, Issue 7, 2000, Pages 1008-1014

  Mohr, Leonhard ^a,e   Rainov, Nikolai G ^b,c   Mohr, Ursula G ^a   Wands, Jack R ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d Liver Research Center Brown University Medical School   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

4 ipomeanol; Cytochrome P450; Hepatoma; Suicide gene; Tumor gene therapy

Indexed keywords

4 IPOMEANOL; CYTOCHROME P450 ISOENZYME; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; PRODRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVATION; GENE ACTIVATION; GENE THERAPY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; SUICIDE GENE;

ORYCTOLAGUS CUNICULUS;

EID: 0033914287     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700190     Document Type: Article

References (38)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
2. Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med. 1999;340:798-799.
3. Wands JR, Blum HE. Primary hepatocellular carcinoma. N Engl J Med. 1991;325:729-731.
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
5. Bruix J. Treatment of hepatocellular carcinoma. Hepatology. 1997;25:259-262.
6. Trinchet JC, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J Hepatol. 1997;27: 756-765.
7. Huang CC, Wu MC, Xu GW, et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst. 1992;84:262-264.
8. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol. 1998;16:3674-3690.
9. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429-431.
10. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 1991;338:1356-1359.
11. Ruiz J, Qian C, Prieto J. Gene therapy of liver tumors: principles and applications. Digestion. 1998;59(suppl 2): 92-96.
12. Qian C, Bilbao R, Bruna O, Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology. 1995;22:118-123.
13. Kuriyama S, Nakatani T, Masui K, et al. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology. 1995;22:1838-1846.
14. Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997;57:461-465.
15. Chen SH, Kosai K, Xu B, et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 1996;56:3758-3762.
16. Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst. 1998;90:370-380.
17. O'Malley BW, Cope KA, Chen SH, Li D, Schwarta MR, Woo SL. Combination gene therapy for oral cancer in a murine model. Cancer Res. 1996;56:1737-1741.
18. Uckert W, Kammertons T, Haack K, et al. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther. 1998; 9:855-865.
19. Rainov NG, Dobberstein KU, Sena-Esteves M, et al. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther. 1998;9:1261-1273.
20. Boyd MR, Burka LT. In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol. J Pharmacol Exp Ther. 1978;207:687-697.
21. Czerwinski M, McLemore TL, Philpot RM, et al. Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. Cancer Res. 1991;51:4636-4638.
22. Rainov NG, Sena-Esteves M, Fraefel C, Dobberstein KU, Chiocca EA, Breakefield XO. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Adv Exp Med Biol. 1998;451: 393-403.
23. Serabjit-Singh CJ, Wolf CR, Philpot RM, Plopper CG. Cytochrome p-450: localization in rabbit lung. Science. 1980;207:1469-1470.
24. Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99:403-413.
25. Verschoyle RD, Philpot RM, Wolf CR, Dinsdale D. CYP4B1 activates 4-ipomeanol in rat lung. Toxicol Appl Pharmacol. 1993;123:193-198.
26. Kasturi VK, Dearing MP, Piscitelli SC, et al. Phase I study of a five-day dose schedule of 4-ipomeanol in patients with non-small cell lung cancer. Clin Cancer Res. 1998;4:2095-2102.
27. Rowinsky EK, Noe DA, Ettinger DS, et al. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. Cancer Res. 1993;53:1794-1801.
28. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther. 1993;4:725-731.
29. Kim JH, Chung JB, Park IS, et al. Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines. Yonsei Med J. 1993;34:35-44.
30. Boyd MR. Role of metabolic activation in the pathogenesis of chemically induced pulmonary disease: mechanism of action of the lung-toxic furan, 4-ipomeanol. Environ Health Perspect. 1976;16:127-138.
31. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523-526.
32. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 1992;52:6358-6364.
33. Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998;188:2033-2045.
34. Ponchel F, Puisieux A, Tabone E, et al. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor β1-mediated apoptosis. Cancer Res. 1994;54:2064-2068.
35. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
36. Buckpitt AR, Boyd MR. The in vitro formation of glutathione conjugates with the microsomally activated pulmonary bronchiolar alkylating agent and cytotoxin, 4-ipomeanol. J Pharmacol Exp Ther. 1980;215:97-103.
37. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev. 1996;6: 610-617.
38. Dutcher JS, Boyd MR. Species and strain differences in target organ alkylation and toxicity by 4-ipomeanol. Biochem Pharmacol. 1979;28:3367-3372.